billHR10086Event Thursday, August 13, 2026Analyzed

Diabetes Prevention Program Reauthorization Act of 2026

Neutral

Summary

H.R. 10086 authorizes up to $246.5 million over five years for the CDC's National Diabetes Prevention Program, but remains in early committee stage and requires separate appropriations. The funding is too small relative to healthcare sector revenues to produce a material impact on any publicly traded company.

See which stocks are affected

Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.

Already have an account? Log in

Key Takeaways

  • 1.Bill authorizes $246.5M over 5 years for diabetes prevention, but is early-stage and not yet funded.
  • 2.Funding is negligible relative to healthcare sector revenues; no single company stands to benefit materially.
  • 3.Investors should monitor appropriations process and potential expansion, but no immediate action warranted.

Market Implications

The bill has no near-term market implications. Even if fully appropriated, the annual funding ($39M–$59M) is a rounding error for large-cap healthcare companies. Investors should not adjust positions based on this legislation.

Full Analysis

On August 13, 2026, Rep. De La Cruz (R-TX) introduced H.R. 10086, the Diabetes Prevention Program Reauthorization Act of 2026, which was referred to the House Committee on Energy and Commerce. The bill amends the Public Health Service Act to authorize specific funding levels for the National Diabetes Prevention Program (DPP): $39.3 million for FY2027, escalating to $59.3 million by FY2031, totaling $246.5 million over five years. This is an authorization bill, not an appropriation—actual spending requires a separate appropriations bill. The program is administered by the CDC and funds community-based lifestyle change interventions. While the DPP has demonstrated effectiveness in reducing diabetes incidence, the authorized amounts are modest in the context of the $4.5 trillion U.S. healthcare market. Major health insurers and wellness companies (e.g., UnitedHealth Group, Humana, CVS Health, WW International) operate DPP programs, but the incremental federal funding represents less than 0.01% of their annual revenues. No convergence signals were provided. The legislative path is lengthy: committee markup, House floor vote, Senate passage, and presidential signature. Given the early stage and small funding, no actionable market impact exists for retail investors.

Key Legislators

Rep. De La Cruz, Monica [R-TX-15]

Related Presidential Actions

Executive orders & memoranda affecting the same sectors or companies

Exec OrderAug 10, 2026

Delivering Gold Standard Childhood Vaccine Recommendations for Americans

This executive order directs HHS to establish a 'Gold Standard' childhood vaccine schedule with fewer recommended vaccines than current CDC guidelines, mandates that MMR be administered as three separate single-disease shots when domestically available, and instructs the DOJ to challenge state vaccine mandates that do not provide religious or medical exemptions. It also orders HHS to develop alternative adjuvants to aluminum and improve vaccine safety monitoring, while preserving access to existing vaccines.

Exec OrderAug 6, 2026

Continuing to Protect the Meaning and Value of American Citizenship

This executive order directs federal agencies, including State, Justice, Homeland Security, and Social Security, to deny U.S. citizenship documentation to children born in the U.S. whose parents include alien enemies, foreign government employees, or those involved in commercial birth tourism or surrogacy, or who are born in territories without statutory citizenship. It implements a narrow interpretation of the Fourteenth Amendment following the Supreme Court's decision in Trump v. Barbara, effectively restricting birthright citizenship for specific categories of non-citizen parents.

Exec OrderAug 6, 2026

Ending Birth Tourism

This executive order directs the Secretaries of State and Homeland Security to prevent foreign nationals from entering the U.S. on nonimmigrant visas for the purpose of giving birth (birth tourism), including revoking visas, barring entry, and taking action against facilitators. It defines birth tourism as entry via nonimmigrant visa for childbirth and allows humanitarian or national interest exemptions.

Free — no credit card

Get the next market-moving signal before the news does

HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.

Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.

Free forever plan · No credit card · Unsubscribe in one click

Want the live terminal too? Create a free account →